• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Provident Financial Services

Provident Financial Services

Provident Financial Services Inc PFS

Last Price$18.41Day Change (%)-0.11%
Open Price$18.46Day Change ($)-0.02
Day Range18.26–18.5452-Week Range16.06–19.05

As of Fri 3/27/2015 5:26:00 PM | USD

  1. All
  2. Morningstar Articles
  3. 3rd Party
  4. Investing
  1. Cerulean Reports Fourth Quarter 2014 Corporate Highlights and Financial Results

    Cerulean Reports Fourth Quarter 2014 Corporate Highlights and Financial Results

  2. Bernstein Liebhard LLP Investigates Claims On Behalf Of Those Who Invested In Nektar Therapeutics

    Bernstein Liebhard LLP Investigates Claims On Behalf Of Those Who Invested In Nektar Therapeutics

  3. Independent Data Monitoring Committee Unanimously Recommends Unblinding of IMBRUVICA® (ibrutinib) Phase III Combination HELIOS Trial Based on Interim Analysis Showing Significant Improvement in ...

    Independent Data Monitoring Committee Unanimously Recommends Unblinding of IMBRUVICA® (ibrutinib) Phase III Combination HELIOS Trial Based on Interim Analysis Showing Significant Improvement in Progression-Free Survival in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

  4. CytRx Reports 2014 Financial Results

    CytRx Reports 2014 Financial Results

  5. AVEO Oncology Reports Full Year 2014 Financial Results

    AVEO Oncology Reports Full Year 2014 Financial Results

  6. OncoTherapy Network Highlights Kidney Cancer Awareness Month

    OncoTherapy Network Highlights Kidney Cancer Awareness Month

  7. Phase 3 Head-to-Head ENDEAVOR Study Demonstrates Superiority Of Kyprolis® (carfilzomib) Over Velcade® (bortezomib) In Patients With Relapsed Multiple Myeloma

    Phase 3 Head-to-Head ENDEAVOR Study Demonstrates Superiority Of Kyprolis® (carfilzomib) Over Velcade® (bortezomib) In Patients With Relapsed Multiple Myeloma

  8. Ipsen’s 2014 Results and 2015 Financial Objectives

    Ipsen’s 2014 Results and 2015 Financial Objectives

  9. Acceleron Presents Encouraging Response Rates and Progression-Free Survival Data in Patients with Advanced Renal Cell Carcinoma at the American Society of Clinical Oncology (ASCO) 2015 Genitourinary ...

    Acceleron Presents Encouraging Response Rates and Progression-Free Survival Data in Patients with Advanced Renal Cell Carcinoma at the American Society of Clinical Oncology (ASCO) 2015 Genitourinary Cancers Symposium

  10. NAPFA’s CFP-Only Stand: A Step in the Wrong Direction

    A curious move, at a curious time, for purportedly, a curious reason, that is also a slap in the face to CPAs with the PFS credential.

123
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.